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The long-term success of arthroplastic joints is dependent on the stabilization of the implant within the skeletal site. Movement of
the arthroplastic implant within the bone can stimulate osteolysis, and therefore methods which promote rigid ﬁxation or bone
growth are expected to enhance implant stability and the long-term success of joint arthroplasty. In the present study, we used a
simplebilateralbonedefectmodeltoanalyzetheosteogenicactivityofthreesmall-moleculedrugimplantsviamicrocomputerized
tomography (micro-CT) and histomorphometry. In this study, we show that local delivery of alendronate, but not lovastatin or
omeprazole, led to signiﬁcant new bone formation at the defect site. Since alendronate impedes osteoclast-development, it is
theorized that alendronate treatment results in a net increase in bone formation by preventing osteoclast mediated remodeling of
the newly formed bone and upregulating osteoblasts.
1.Introduction
Bone remodeling is a delicate balance of two processes: bone
deposition by osteoblasts and bone resorption by osteoclasts
[1–3]. This equilibrium is regulated by local and systemic
factors which inﬂuence the diﬀerentiation and activity of
osteoblasts derived from mesenchymal cells and osteoclasts
derived from hematopoietic precursors [4]. Manipulation
of either of these processes can result in a net increase in
bone formation. Moreover, modulation of these processes
can be targeted to create therapeutic interventions to treat
diseases associated with bone loss, such as osteoporosis,
or to enhance arthroplasty success, where bone growth
aroundthearthroplasticimplantisneededtopromotebetter
ﬁxation.
A critical factor for long-term success of arthroplastic
joints is rigid stabilization of the implant within the skeletal
site [5]. Osteolysis around arthroplastic implants leads to de-
stabilization of the joint and necessitates revision surgery [6–
9]. It is thought that movement of the arthroplastic implant
within the bone can stimulate osteoclast activity or lead
to abnormal implant wear, which in turn produces wear
debris and an osteolytic inﬂammatory reaction [6]. Physical
methods to promote rigid ﬁxation of arthroplastic implants
include press-ﬁt implantation, screw augmentation, and
cementing [10, 11]. Other methods promote bone growth
around the arthroplastic implant to promote rigid ﬁxation,
which include modifying the implant surface to promote
osseous integration [12] and, more recently, coating the
surface of the implant with an osteoconductive material,
such as hydroxyapatite [13, 14]. It is hypothesized that
methodsthatwouldpromoteboneformationintooraround
anarthroplasticimplantwouldenhanceimplantstabilityand
increase the long-term success of joint arthroplasty.2 Journal of Biomedicine and Biotechnology
A potential method to enhance arthroplastic implant
ﬁxation would be use of pharmaceutical compounds that
increase net bone formation into or around an arthroplastic
implant. Such pharmaceutical compounds could be incor-
porated into the design of the implant or applied as an
additionalstepduringarthroplasticsurgery.Thepharmaceu-
ticals could be bisphosphonates or proton pump inhibitors
(PPIs) that interfere with osteoclast activity to increase
bone density or statins that increase osteoblast activity.
Nitrogen-containing bisphosphonates, such as alendronate,
reduce osteoclastic resorption by speciﬁcally inhibiting far-
nesyl pyrophosphate synthase which disrupts key regulatory
proteins and leads to osteoclast inactivity and apoptosis
[15]. Diseases associated with excessive bone resorption,
such as Paget’s disease, myeloma, and osteoporosis, are
currently treated with systemically delivered bisphospho-
nates [16]. Locally applied bisphosphonates also can inhibit
bone resorption [17–19]. Osteoclasts resorb bone through
the action of proton pumps that acidify the extracellular
environment within the ruﬄed border zone [15]. Thus
inhibiting the activity of proton pumps may also impair
osteoclastactivity.OmeprazoleisagastricPPIcurrentlyused
to treat acid-related diseases such as peptic ulcer diseases and
gastroesophageal reﬂux [20]. This drug inhibits various pro-
tein pumps including the vacuolar-type H(+)-ATPase which
is important in the formation of the acidic environment in
the extracellular ruﬄed border zone of osteoclasts [21–25].
Statins, like lovastatin, inhibit HMG-CoA reductase and are
thought to shunt uncommitted osteoprogenitor cells in the
marrow to osteoblastic diﬀerentiation leading to a positive
eﬀect on bone formation [26]. Research has shown that
statinscanincreaseboneformationinvitroandinvivowhen
given locally or in very large doses systemically [27, 28].
Statins have also been shown to increase the expression of
BMP-2 which can positively aﬀect bone formation [29, 30].
As a ﬁrst step to developing new pharmaceutical en-
hancements for arthroplastic implant ﬁxation, the present
study examined whether local application of a bisphos-
phonate, (alendronate), a PPI (omeprazole), or a statin
(lovastatin) could increase local bone formation in a cortical
bone defect model.
2.MaterialsandMethods
2.1. Hydrogel Implant Preparation. All blanks and drug-
laden implants were produced at Ethicon (Somerville, NJ).
For blank implants, sodium hyaluronate powder (Novama-
trix, Pharma 150) was weighed (2.0grams) and transferred
tothelargemixingbowlofaCalevaMixerTorqueRheometer
(MTR) while mixer paddles were turning at 50rpm. A 1:1
mixture of ethanol and distilled water was prepared and 3ml
of the solution was added to the mixing powder in 0.5ml
aliquots. Wet granulation was removed from large mixing
bowl and the Caleva MTR was reﬁtted with the extruder
accessory. The wet granulation was placed in the hopper of
the extruder with a single screw turning at 50rpm. A die
with a conﬁguration of 3mm holes was placed at the end of
the extruder screw and wet granulation was extruded into 3
strands of 3mm in diameter. Strands were immediately cut
into 3mm pellet lengths and placed in a vacuum oven for
overnight drying. The average weight of implants was 10.0 ±
1.4mg.
For each drug-laden implant, alendronate, lovastatin,
or omeprazole (Sigma, St. Louis, MO) was weighed and
dissolved in 4ml of a 1:1 ethanol water solution and
added to 2.5grams sodium hyaluronate in 0.5ml aliquots as
described above. At the higher concentration of alendronate,
5.75mg of active compound was dispersed in 2.5grams of
sodium hyaluronate (0.23% w/w). At the lower concentra-
tion 1.35mg of alendronate was dispersed in 2.5grams of
sodium hyaluronate (0.05% w/w). The average mass of the
higher and lower concentration pellets was 11.4 ± 0.6 and
13.6 ± 0.8mg, respectively. At the higher concentration of
lovastatin, 11.56mg of active compound was dispersed in
2.5grams of sodium hyaluronate (0.5% w/w). At the lower
concentration1.3mgoflovastatinwasdispersedin2.5grams
of sodium hyaluronate (0.05% w/w). The average mass of
the higher and lower concentration pellets was 13.0 ± 0.7
and 16.1 ± 0.5 mg, respectively. At the higher concentration
of omeprazole, 26.71mg of active compound was dispersed
in 2.5grams of sodium hyaluronate (1% w/w). At the
lower concentration 2.71mg of omeprazole was dispersed in
2.5grams of sodium hyaluronate (0.1% w/w). The average
massofthehigherandlowerconcentrationpelletswas13.7±
0.6 and 14.6 ± 0.5mg, respectively. The concentration of the
active compound within drug-laden implants was conﬁrmed
by HPLC analysis.
2.2. Coating of Pellets. Poly (lactide co-glycolide) (PLGA)
was dissolved in ethyl acetate to the target concentration.
The pellets were individually placed in respective 1.5ml
siliconized polypropylene microcentrifuge tubes. Five pellets
were placed on a teﬂon substrate. A pipette was used to coat
the pellet with the coating solution. The volume of each
coating application was 50ul. Pellets were vortexed in the
closed microcentrifuge tube in order to more uniformly coat
the pellet. Pellets were dried in a ventilated hood for 2-3
hours followed by drying overnight in a vacuum oven at
room temperature. Afterwards, the exterior bottom of the
microcentrifuge tube was dipped quickly in liquid nitrogen
to dislodge the pellet from the tube.
2.3. Animal Procedures. Male Sprague-Dawley rats that
weighed 544 ± 52 grams at the time of surgery and 555
± 56 grams when euthanized 3 weeks later were used.
The rats were housed in pairs, maintained in a 12-hour
light dark cycle, and provided food and water ad libitum.
All animal procedures were approved by the UMDNJ-New
Jersey Medical School Institutional Animal Care and Use
Committee prior to initiation of the project.
Bilateral defects were made in the distal femur of each
rat to assess local drug eﬀects on bone formation. Rats
were anesthetized by intraperitoneal injection of ketamine
(50mg/kg) and xylazine (10mg/kg). Hind limbs were pre-
pared for surgery by shaving the knee areas and scrubbing
with betadine. A lateral 1cm incision was created above
the knee on each thigh. The overlying muscle was bluntly
dissected to the surface of the distal femur. Using a 3mmJournal of Biomedicine and Biotechnology 3
diameter burr and a variable speed drill (Dremel, Racine,
WI), a defect in the lateral aspect of each femur was created
through the cortical bone to expose the marrow cavity [31].
Each defect site was irrigated with saline and sponged dry
with gauze. A dry hydrogel implant was inserted into the
defect with the aid of a 1cc tuberculin syringe (without nee-
dle)moistenedatthetipwithsaline.Thewoundswereclosed
in two layers with resorbable sutures. Radiographs of each
animal were made to conﬁrm and record the initial defect.
Seventreatmentgroupsweretested:(a)emptydefect,(b)
low-dose alendronate (7ug/implant), (c) high-dose alendro-
nate(26ug/implant),(d)low-doselovastatin(8ug/implant),
(e) high-dose lovastatin (65ug/implant), (f) low-dose
omeprazole (15ug/implant), and (g) high-dose omeprazole
(137ug/implant). Each rat received a placebo hydrogel
implant(blank)andoneoftheabovetreatments.Treatments
were randomized to each animal, and implantation of the
blank was randomized to the left or right femur. In order
to determine if drug treatment enhanced healing, rats were
euthanized when the blank implant ﬁlled defects appeared to
be undergoing healing but were not yet fully healed. Based
on a pilot study, burr defects ﬁlled with blank implants were
actively healing at 3 weeks but not fully healed. Therefore, six
to eight rats were used per treatment group and all rats were
euthanized and femurs analyzed at 3 weeks post surgery.
2.4. Micro-Computed Tomography. Resected femurs were
cleaned of soft tissue without disturbing the surgical site
andphotographedtorecordanygross,macroscopicﬁndings.
The distal portion of each femur containing the defect
site was removed and ﬁxed in buﬀered formalin. After 4–
7 days of ﬁxation, the femurs were washed in 2 overnight
changes of 70% ethanol prior to microcomputerized tomog-
raphy (microCT) analysis (SCANCO, Wayne, PA). Three-
dimensional μCT images were made to analyze the bone
mineral density (BMD) and bone volume (BV) of the defect
site. The specimens were scanned in 70% ethanol to prevent
drying. All samples were scanned on a Scanco Medical μCT
40 system at an energy of 55Kvp and intensity of 145μA
with a voxel size of 16 microns isotropic using a 0.5mm
Al ﬁlter. Cone-Bean reconstruction was performed. All scan
and reconstruction parameters applied were identical for
all specimens. The data was analyzed using the Scanco
Analysis Software bundled with the microCT system. The
scanneracquisitionandsoftwarehadbuilt-inimageintensity
to density conversion capability which enabled quantitative
analysis of BMD in units of HAmg/cc. The region of interest
(ROI) was speciﬁed as ﬁxed distance of 4.4mm (275 slices
per specimen) and was consistent between samples. In this
area BMD and BV were determined. BMD is deﬁned as
the amount of bone mineral per unit volume of bone
tissue (g/cm3). In addition, BV(mm3) was expressed as a
percentage of the total ROI volume.
2.5. Histological Procedures. Following microCT scanning,
samples were embedded in polymethylmethacrylate
(PMMA) following standard procedures [32]. A single
section was cut through the defect site perpendicular to
the long axis of the femur. Sections were polished and
stained with van Gieson’s picrofuchsin to stain mineralized
tissue red and Stevenel’s blue to stain cartilage deep blue
[33–35]. The amount of new bone measured within the
defect (deﬁned as all bone within ROI-1 in Figure 4(a)-left)
and on the periphery (deﬁned as all bone outside of ROI-2
in Figure 4(b)-right) was measured by histomorphometric
analysis of digital images using Image Pro software (version
5.0, Media Cybernetics, Inc., Bethesda, MD).
2.6. Data Analysis. Data were compared between the blank
values of the empty defect group and the blank values of the
treatment groups using an analysis of variance (ANOVA).
This comparison determined whether any treatment had
as y s t e m i ce ﬀect. Local osteogenic eﬀects were identiﬁed
by comparing experimental and blank pellets using a t-test
within a treatment group.
3. Results
3.1. Drug Release and Elution Analysis. In vitro release of
omeprazole and lovastatin from the implants was measured
by HPLC (data not shown). Alendronate could not be
detectedusingUVorvisiblelightspectrometryandtherefore
was not analyzed using this method. Instead the in vitro
release of alendronate was measured by liquid chromatog-
raphy -mass spectrometry. The data demonstrated that a
burst of drug was released on day one which declined
by day three. This trend was observed regardless of the
drug, concentration of drug (high or low dose levels), or
percent PLGA coating. Overall, these studies showed that
drug release from implants did not occur by simple diﬀusion
from the hyaluronate pellets. Instead there appeared to be a
strong drug-polymer interaction which made drug release,
following the initial burst release, dependent on degradation
of the implant. Since coating the implants with PLGA had no
impact on drug release rate, the implants used in this study
were left uncoated.
3.2. Observations regarding the Surgical Procedure. The sur-
gical procedure was easily accomplished and well tolerated
by the rats. Implantation of the hydrogel-drug implants was
accomplished by touching one end of the dry implant with
the end of a 1cc tuberculin syringe (without needle) that
had been dipped in saline. The implant “stuck” to the end of
the syringe and allowed it to be easily placed into the defect.
It was noted that the heavier implants were more diﬃcult
to implant into the defect which was likely related to the
increased diameter of the implant.
3.3. Disposition of Animals and Femur Samples. The exper-
imental design and loss of animals in the study are
summarized in Table 1. One anticipated complication was
postsurgical fracture which occurred in 3 of the 90 femurs
used in the study. Two fractures occurred in the alendronate
t r e a t m e n tg r o u p sa n do n ei nac o n t r o lb l a n kf e m u ro ft h e
omeprazole treatment group. Only one of the 90 femurs
developed an infection. Two rats died from the surgical
anesthesia after the surgical procedure was complete, that
is, the animals never regained consciousness. Finally, femurs4 Journal of Biomedicine and Biotechnology
Table 1: Summary of Animal Disposition.
Postsurgical
Treatment versus Blank Initial Group Size Morbidity & Mortality Histology Error Group Size for Each Analysis
Fracture Infection Anesthesia Other microCT Histomorph.
Empty Defect 6 0 0 0 1 0 5 5
Low-Dose Alendronate 6 1 (Rx) 1 0 0 1 4 3
High-Dose Alendronate 6 1 (Rx) 0 0 0 0 5 5
Low-Dose Lovastatin 6 0 0 0 0 0 6 6
High-Dose Lovastatin 7 0 0 1 0 0 6 6
Low-Dose Omeprazole 6 0 0 0 0 0 6 6
High-Dose Omeprazole 8 1 (Bl ) 0 1 0 1 6 5
Totals 45 3 1 2 1 2 38 35
from two rats were not used because the defect could not
be located after resection of the femur. Immediate post-
operative radiographs conﬁrmed that the rats indeed had
bilateral femur defects. Yet for two femurs, no defect could
be observed after 3 weeks of healing suggesting that the
defect had completely healed. One of the completely healed
defects was a blank of the high-dose omeprazole group and
the other was a blank defect in the low-dose alendronate
group.
3.4. Radiographic Observations of the Healing Defects. Radio-
graphs were made for each animal immediately after surgery
and again at 3 weeks (Figure 1). Defects were plainly
evident in most radiographs. Visual evidence of healing
also was apparent in most of the radiographs. However, the
radiographsappearedtopresentaspectrumofhealingrather
than having distinct classes of healed (Figure 1(c))v e r s u s
not healed (Figure 1(b)). Beyond using these radiographs
to identify postsurgical complications, such as fractures or
infections, the radiographs were not scored or in any other
way correlated to the experimental treatments.
3.5. Microcomputerized Tomography (microCT) Analysis of
the Healing Defects. The primary outcome measure was
microCT quantiﬁcation of new bone at the defect site for
each femur. In addition, bone mineral density of the newly
formed bone also was measured. Femurs were scanned in a
blindedfashioninthattheoperatorwasunawareofthetreat-
mentsusedineachfemur.Representative3Dreconstructions
of an empty defect, blank-treated defect, and defects from
the high-dose drug treatment groups are shown in Figure 2.
The experimental design enabled a direct comparison of
new bone formation by comparing femur defects treated
with drug (or left empty) with its contralateral femur defect
treated with a blank. Treatment and blank defect new bone
volumes were compared with t-tests (Table 2 and Figure 3).
The data indicate that only alendronate treatment, either
low or high dose, led to signiﬁcantly more bone formation
at the defect site. Analysis of variance (ANOVA) and post
hoc Holm-Sidak tests of bone formation found that only
the alendronate groups were signiﬁcantly diﬀerent than all
other treatment groups (P < .001 and P = .003) but that
(a)
(b)
(c)
Figure 1: Post-Surgery Radiographs. Shown are radiographs of
distal femur defects ﬁlled with placebo hydrogel inserts (blanks)
immediate after surgery (a) or 3 weeks later (b-c). The radiographs
revealed a range of healing from partially healed (b), to fully healed
(c). Periosteal bone formation was evident in many samples (b).
no diﬀerence was found between the low- and high-dose
alendronate groups (P = .300).
There were statistically signiﬁcant diﬀerences between
the blank defect bone volumes of the diﬀerent treat-
ment groups (ANOVA P = .043), indicating that locallyJournal of Biomedicine and Biotechnology 5
(a)
(b)
(c)
(d)
(e)
Figure 2: MicroCT Reconstructions of Femur Defects. Femurs were
harvested 3 weeks after surgery and analyzed for bone formation
by microCT. Shown are lateral (left column) and cross-sectional
projections (right column) of (a) an empty defect and defects
treated with (b) a blank, (c) high-dose alendronate, (d) high-dose
lovastatin, and (e) high-dose omeprazole.
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Figure 3: New Bone Volume Quantiﬁed from the MicroCT Analysis
(mm3). The volume of new bone (mm3) formed in each treatment
group (gray bars) was compared to the volume of new bone formed
in the contralateral, blank-treated femurs (black bars) for that
group using Students t-tests. Signiﬁcant P-values are shown (LD:
low-dose; HD: high-dose).
administered omeprazole had a systemic eﬀect on bone
formation. New bone volume in the blank-treated femurs of
the low-dose omeprazole treatment group was signiﬁcantly
greater than that from the blank-treated empty defect group
(P = .004), low-dose lovastatin group (P = .002), and low-
dose alendronate group (P = .020). No diﬀerence in new
bonemineraldensitywasdetectedbetweentreatmentgroups
(Table 3).
3.6. Histomorphometric Analysis of the Healing Defects.
Representative histological sections from an empty defect
and each high-dose treatment group are shown in Figure 4.
New bone was evident in all the samples but little or no
cartilage was visible. New bone area was measured for each
sample and was classiﬁed as being either within the defect
andintramedullarycanal(defectsite,Figure 4(a)-left,shown
as area within ROI-1) or outside the defect (peripheral,
Figure 4(b)-right, shown as the area outside of ROI-2).
Signiﬁcantly more, total (defect site and peripheral), defect
site, and peripheral new bone was measured in the low-
dose alendronate-treated samples as compared to the corre-
sponding blank samples (P = .004, 0.020, and .006, resp.).
In addition, signiﬁcantly more bone was measured in the
defect site of the high-dose alendronate samples (P = .044).
Though the total and peripheral new bone areas were higher
in the high-dose alendronate group, these values were not
signiﬁcantly higher than the contralateral blank defect values
(Figure 5). No other signiﬁcant eﬀects were noted.
4. Discussion
In the present study, local release of antiresorptive and
osteogenic drugs from hydrogel implants was used as an6 Journal of Biomedicine and Biotechnology
Table 2: Eﬀects of Drug Therapy on New Bone Volume.
Treatment Implant
weight (mg)
Percent
drug (w/w)
Approx.
site dose (ug)
Group size Bone volume (mm3; mean ± S.D.) t-test
Drug Blank P value
Empty Defect 00 0 5 2.312 ± 0.810 2.271 ± 0.564 .929
Low-Dose Alendronate 13.6 ± 0.8 0.05 6.8 4 4.749 ± 1.343 2.487 ± 0.952 .033
High-Dose Alendronate 11.4 ± 0.6 0.23 26.2 5 4.893 ± 0.385 2.897 ± 0.125 <.001
Low-Dose Lovastatin 16.1 ± 0.5 0.05 8.0 6 2.833 ± 1.370 2.199 ± 0.409 .303
High-Dose Lovastatin 13.0 ± 0.7 0.5 65 6 2.746 ± 1.410 2.853 ± 0.916 .880
Low-Dose Omeprazole 14.6 ± 0.5 0.1 14.6 6 2.936 ± 0.695 3.722 ± 1.145 .181
High-Dose Omeprazole 13.7 ± 0.6 1 137 6 3.029 ± 0.634 2.833 ± 0.783 .645
Table 3: Eﬀects of Drug Therapy on New Bone Density (mg/cc HA).
Treatment versus Blank Group Size Bone density (mg/cc HA; mean ± S.D.) t-test
Drug Blank P value
Empty Defect 5 998 ± 52 1023 ± 36 0.401
Low-Dose Alendronate 4 966 ± 20 988 ± 32 0.284
High-Dose Alendronate 5 975 ± 42 1012 ± 32 0.156
Low-Dose Lovastatin 6 1027 ± 49 993 ± 16 0.138
High-Dose Lovastatin 6 977 ± 54 1016 ± 45 0.200
Low-Dose Omperazole 6 1018 ± 20 1006 ± 38 0.487
High-Dose Omperazole 6 1003 ± 22 1009 ± 26 0.673
approach to enhance bone formation in a cortical defect
as a preliminary test model for increasing bone formation
around arthroplastic implants. The data demonstrated that
local treatment with the bisphosphonate alendronate led to
signiﬁcantly more new bone at the rat femur defect site as
compared to the controls (both blank and empty defect)
and the other osteogenic drug treatments. Comparison
of total new bone formation at the defect site between
treatment groups found that both doses of alendronate
led to signiﬁcantly more bone formation as compared to
omeprazole or lovastatin.
The paired design of this study controlled for biological
diﬀerences between rats. With this method of local drug
administration, a risk existed for systemic distribution of
the agents that could inﬂuence the bone on the control
(blank) side. However, a separate control group (empty
defect-blank implant) was completed so that we could
analyze the local eﬀects as well as the systemic eﬀects of
each drug. MicroCT analysis of bone volume detected a
positive systemic eﬀect in the control side of the low-dose
omeprazole group. However, no local eﬀect on bone healing
was found with omeprazole treatment. These results suggest
that higher concentrations of omeprazole (such as those
applied locally or that circulate systemically in the high-dose
omeprazole group) do not increase bone formation while a
low concentration (similar to the concentration circulating
systemically in the low-dose omeprazole group) can increase
bone formation. Additional studies are needed to conﬁrm
this apparent omeprazole eﬀect. No systemic eﬀect was
detected for any other treatment groups.
We suspect that the surgical insult produces a signiﬁcant
bone regenerative response in the rats. This response likely
includes a signiﬁcant activation of periosteal osteoblasts and
bone marrow preosteoblasts to form new bone. However,
this ﬂux of osteoblasts would have contributed to bone
formation in all test groups and does not explain the
approximate 2-fold increase in bone volume found in rats
treated with the alendronate hydrogel implants.
The mechanism by which alendronate increased bone
formation was not investigated in these studies. Alendronate
is expected to prevent osteoclast mediated remodeling of
the newly formed bone, which could in part account for
the increased amount of mineralized tissue measured in
the alendronate treatment groups [36, 37]. Alendronate
and other nitrogen-containing bisphosphonates also can
increase osteoblast proliferation [38–40], prevent osteoblast
apoptosis [41, 42], inhibit diﬀerentiation of mesenchymal
stem cells into adipocytes [43, 44], and promote osteoblast
diﬀerentiation and activity including enhancing expression
of Runx2 and BMP-2 [39, 40, 45, 46]. Alendronate eﬀects
on osteoblasts appear to be mediated through ERK and
JNK activation and alteration of the mevalonate pathway
[38,41,42,44,47].Thus,alendronatecanhavebothanabolic
and anticatabolic eﬀects on bone.
We suggest that local alendronate treatment enhanced
bone formation and reduced osteoclast-mediated remodel-
ing at the cortical defect site leading to a large increase in
bone formation. Our results are similar to those of Jakobsen
et al. who demonstrate that local alendronate treatment
increased ﬁxation of implants inserted in cancellous boneJournal of Biomedicine and Biotechnology 7
Treatment Blank
ROI-1 ROI-2
(a)
Treatment Blank
(b)
Treatment Blank
(c)
Treatment Blank
(d)
Figure 4: Histological Sections of Femur Defects. Following micro CT evaluation, specimens were plastic embedded, sectioned through the
defect, and stained for mineralized tissue (red) and cartilage (deep blue). Shown are representative cross-sections from (a) an empty defect
and defects treated with (b) high-dose alendronate, (c) high-dose lovastatin, and (d) high-dose omeprazole. ROI-1 is shown and included
the defect site and marrow space (a)-left. ROI-2 is shown and bone outside of ROI-2 was considered peripheral bone formation (a)-right.
Corresponding blank-treated defects from each treatment group are shown in the right column. Mineralized tissue was evident in all defect
sites but little or no cartilage was observed.8 Journal of Biomedicine and Biotechnology
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Figure 5: Histomorphometric Analysis of Bone Formation. Areas of new bone formation were measured from cross-sections of each femur
defect. The total new bone area (a) was further categorized as being within the defect site and marrow space (b) or on the femur periphery
(c). New bone area for each treatment group (gray bars) was compared to the new bone area in thecontralateral, blank-treated femurs (black
bars) for that group using Students t-tests. Signiﬁcant P values are shown (low-dose, LD; high-dose, HD).
after 4 and 12 weeks in a canine model by increasing
bone volume and density [17, 18]. These results contrast
a rabbit femoral condyle study where alendronate had
no positive eﬀect when it was incorporated into bone
cement and inserted into the defect. However, in this
rabbit study, alendronate appeared to evoke a toxic response
which may have contributed to the absence of a positive
bone healing response [15]. This suggests that alendronate
eﬀect on osteoblast activity may be more important for
increasing bone formation during healing of bone defects
than alendronate eﬀects on osteoclast activity. Future studies
to characterize the cell types and quantify osteoblast- and
osteoclast-related factors at the bone defect site should
provide a better understanding of how these drugs alter the
local bone forming environment.
Since an overall aim of adjuvant therapies for arthro-
plasty is to increase early ﬁxation of these implants and
reduce instability [18, 48], local alendronate treatment could
increase the long-term success of arthroplastic surgeries by
preventingosteolysisandpromotingosteogenesisaroundthe
implant [49–51]. Treatment with lovastatin showed no posi-
tive eﬀects on bone formation at the implant site. Lovastatin
is expected to promote osteoblast activity by inducing BMP-
2 expression but would not directly aﬀect osteoclast activity
[28]. Previous studies have shown that large doses of orally
administered lovastatin can stimulate bone formation [28].
If lovastatin did induce a large bone formation response
in this study, it is possible that subsequent osteoclast
mediated remodeling may have destroyed most of the initial
bone. The data indicate that this hypothesis is unlikelyJournal of Biomedicine and Biotechnology 9
since bone remodeling would have likely led to increased
bone mineral density and no such increase was observed
(Table 3). Lovastatin concentration may have contributed
to the lack of bone formation. The highest concentration
of lovastatin incorporated per implant was approximately
0.01mg/kg body weight. This is similar to the dose used
by Gutierrez et al. which demonstrated that 5 consecutive
daysoftransdermallyappliedlovastatin(0.01mg/kgperday)
to ovariectomized rats increased trabecular bone volume
by 30–60% as well as increasing bone formation [27].
However, based on the in vitro elution studies, the largest
portion of the lovastatin dose in this model would have
been released by day 1 (which is expected to be less than
0.01mg/kg) with subsequent smaller daily releases of drug.
Therefore, lovastatin concentration or length of release
may have contributed to the absence of increased bone
formation.
Experimentally, omeprazole produced no consistent
eﬀect on bone formation. Omeprazole is expected to inhibit
proton pumps (H+K+ATPase) in osteoclasts and prevent
bone resorption [52]. The large amount of new bone
volume in the blank-treated defects of the low-dose omepra-
zole treatment group as compared to the blank-treated
defects from the empty (P = .004), low-dose alendronate
(P = .020), and low-dose lovastatin (P = .002) groups was
unexpected (see Table 2 and Figure 3). This elevation sug-
g e s t sas y s t e m i ce ﬀect of low-dose omeprazole, but a similar
eﬀect was not found in the high-dose omeprazole. One
plausible explanation is that the local omeprazole concen-
trations as well as the systemic levels of omeprazole in the
high-dose group were too high to promote formation. If
this is true, lower doses of omeprazole may help promote
bone formation. This hypothesis will require additional
investigation.
Alendronate treatment was superior to lovastatin or
omeprazole in this in vivo assay of bone formation. Peter
et al. found that local zoledronate (another bisphosphonate)
doses of 0.2 and 2.0ug were not eﬀective in promoting
osteogenesis while doses of 8.5ug and higher (maximum
testedwas16ug)allstimulatedosteogenesis[53].Incontrast,
Bodde et al. found that a local alendronate dose of 8.2mg
inhibited bone formation in a rabbit femoral condyle defect
model [15]. Consequently we tested alendronate using 6.8
and 26.2ug doses to identify any potential dose response
eﬀects in this dose range or any potential negative eﬀect of
the drug. Similar to Peter et al. [53] , we found that both
bisphosphonatedosesincreasedboneformationatthedefect
site. Nominally, bisphosphonates can be incorporated into
bone, and since the defect site is actively producing new
bone, it is likely that release of alendronate from the implant
led to a locally high concentration of drug that remained
at the site. In contrast, lovastatin and omeprazole are not
known to be incorporated into the bone matrix. Thus the
eﬀectivereleasekinetics betweenalendronate,lovastatin,and
omeprazole are likely very diﬀerent. In addition, preliminary
in vitro studies indicated a sharp burst of drug release
initially from the pellets which dropped oﬀ precipitously
(within three days). Therefore, additional experiments to
test implants that show a longer-lasting release of lovastatin
or omeprazole may show that these compounds also are
eﬀective osteogenic compounds.
This study screened 3 drugs for potential use as agents
to enhance local bone formation. As such, the study has
signiﬁcant limitations. First, the study design used only a
single time point, which may not have captured early or
later positive eﬀects of the drugs. There is also the concern
whether results from rodent models will translate to similar
eﬀects in humans. The rat femur lacks large amounts of
trabecular bone that is typically found in the metaphyses
of human long bones. Consequently, the drugs in this
study appeared to primarily aﬀect cortical bone rather than
trabecular bone as would be expected in humans undergoing
anarthroplasticprocedure.Thebilateralexperimentaldesign
controlled for potential drug systemic eﬀects; however,
systemic and local drug levels were not measured in vivo.
Drug release data would be helpful in designing future
studies and for comparing drug eﬀects when released from
diﬀerent carriers or when used in diﬀerent models.
5. Conclusions
Our data demonstrates that treatment with alendronate led
to a signiﬁcant increase in defect site bone volume while
omeprazole or lovastatin treatment had no signiﬁcant eﬀect
on bone formation in this model using the hydrogel carrier.
Local alendronate treatment may be useful in increasing
the outcome success of arthroplastic surgeries by preventing
osteolysis around the skeletal surgical site. Further analysis of
lovastatin and omeprazole would be necessary to determine
their eﬃcacy at promoting bone formation in this model.
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